CN100506790C - 莫达非尼多晶型 - Google Patents

莫达非尼多晶型 Download PDF

Info

Publication number
CN100506790C
CN100506790C CNB038190850A CN03819085A CN100506790C CN 100506790 C CN100506790 C CN 100506790C CN B038190850 A CNB038190850 A CN B038190850A CN 03819085 A CN03819085 A CN 03819085A CN 100506790 C CN100506790 C CN 100506790C
Authority
CN
China
Prior art keywords
modafinil
type
solvate
solvent
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038190850A
Other languages
English (en)
Chinese (zh)
Other versions
CN1675177A (zh
Inventor
M·布罗夸尔
L·克沃斯尔
A·弗莱德曼
G·柯库艾尔
F·茂莱特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saifulun European Co
Teva Sante SAS
Original Assignee
Osmond World Synthetic Organization
Cephalon France SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osmond World Synthetic Organization, Cephalon France SAS filed Critical Osmond World Synthetic Organization
Publication of CN1675177A publication Critical patent/CN1675177A/zh
Application granted granted Critical
Publication of CN100506790C publication Critical patent/CN100506790C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/06—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CNB038190850A 2002-08-09 2003-08-08 莫达非尼多晶型 Expired - Fee Related CN100506790C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40206402P 2002-08-09 2002-08-09
US60/402,064 2002-08-09
US10/635,445 2003-08-07
US10/635,445 US6992219B2 (en) 2002-08-09 2003-08-07 Modafinil polymorphic forms

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN 200910203850 Division CN101619033B (zh) 2002-08-09 2003-08-08 莫达非尼多晶型
CN2012103955547A Division CN102875430A (zh) 2002-08-09 2003-08-08 莫达非尼多晶型
CN201210395545.8A Division CN102875429B (zh) 2002-08-09 2003-08-08 莫达非尼多晶型

Publications (2)

Publication Number Publication Date
CN1675177A CN1675177A (zh) 2005-09-28
CN100506790C true CN100506790C (zh) 2009-07-01

Family

ID=31720568

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB038190850A Expired - Fee Related CN100506790C (zh) 2002-08-09 2003-08-08 莫达非尼多晶型
CN201210395545.8A Expired - Fee Related CN102875429B (zh) 2002-08-09 2003-08-08 莫达非尼多晶型
CN2012103955547A Pending CN102875430A (zh) 2002-08-09 2003-08-08 莫达非尼多晶型

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201210395545.8A Expired - Fee Related CN102875429B (zh) 2002-08-09 2003-08-08 莫达非尼多晶型
CN2012103955547A Pending CN102875430A (zh) 2002-08-09 2003-08-08 莫达非尼多晶型

Country Status (11)

Country Link
US (3) US6992219B2 (https=)
EP (2) EP1575915A1 (https=)
JP (2) JP4718177B2 (https=)
CN (3) CN100506790C (https=)
AU (1) AU2003253128B2 (https=)
CA (4) CA2804385A1 (https=)
IL (3) IL166301A (https=)
MX (1) MXPA05001506A (https=)
NZ (1) NZ537840A (https=)
WO (1) WO2004014846A1 (https=)
ZA (1) ZA200500411B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2003529A3 (cs) 2000-07-27 2003-09-17 Teva Pharmaceutical Industries Ltd. Krystalický a čistý modafinil a postup jeho přípravy
JP4498679B2 (ja) * 2001-03-27 2010-07-07 大日本住友製薬株式会社 結晶性イソキサゾール誘導体およびその医薬製剤
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
FR2849029B1 (fr) 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
US7244865B2 (en) * 2003-02-24 2007-07-17 Mallinckrodt Inc. Process for preparing benzhydrylthioacetamide
WO2004083183A1 (en) * 2003-03-21 2004-09-30 Hetero Drugs Limited Novel crystalline forms of aripiprazole
US20050154052A1 (en) * 2003-03-24 2005-07-14 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US7504516B2 (en) * 2003-03-27 2009-03-17 Hetero Drugs Limited Crystalline forms of candesartan cilexetil
AU2003230195A1 (en) * 2003-04-02 2004-10-25 Hetero Drugs Limited A novel process for amorphous form of donepezil hydrochloride
US7560560B2 (en) * 2003-04-16 2009-07-14 Hetero Drugs Limited Crystalline forms of donepezil hydrochloride
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
ES2330321T3 (es) 2003-05-16 2009-12-09 Cephalon France Procedimiento de sintesis de modafinilo.
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
PT1673370E (pt) 2003-10-16 2009-11-05 Symed Labs Ltd Forma cristalina de linezolida
US20090018202A1 (en) * 2004-02-06 2009-01-15 Cephalon, Inc. Modafinil compositions
EP2292213A1 (en) * 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
WO2005099822A2 (en) * 2004-04-13 2005-10-27 Cephalon, Inc. Reduction of drug / drug interactions with modafinil
WO2005099353A2 (en) * 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
EP1755388B1 (en) * 2004-05-28 2010-10-06 Transform Pharmaceuticals, Inc. Mixed co-crystals and pharmaceutical compositions comprising the same
CA2701710C (en) 2004-07-20 2013-08-27 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US20060235008A1 (en) 2004-08-19 2006-10-19 Hetero Drugs Limited Novel polymorphs of efavirenz
CA2614777C (en) * 2005-07-21 2012-04-17 Neurohealing Pharmaceuticals, Inc. Rapid onset and short term modafinil compositions and methods of use thereof
US7518019B2 (en) * 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
KR20090031618A (ko) * 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 나노입자형 모다피닐 제제
EP2056811B8 (en) * 2006-08-14 2018-03-21 Neurohealing Pharmaceuticals, Inc. Modafinil-based treatment for premature ejaculation
UA110598C2 (uk) 2006-11-10 2016-01-25 Басф Се Спосіб одержання кристалічної модифікації фіпронілу
US8791046B2 (en) 2006-11-10 2014-07-29 Basf Se Crystalline modification of fipronil
JP5931322B2 (ja) 2006-11-10 2016-06-08 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ フィプロニルの結晶変態
WO2008068767A2 (en) * 2006-12-07 2008-06-12 Hetero Drugs Limited A novel crystalline form of lansoprazole
CN101641090B (zh) * 2006-12-19 2012-12-05 亚勒斯有限公司 莫达非尼在制备治疗多动腿综合征的药物中的应用
US20100234468A1 (en) * 2007-06-04 2010-09-16 Abhay Gaitonde Novel process
FR2923482B1 (fr) * 2007-11-09 2010-01-29 Servier Lab Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
US8741329B2 (en) * 2007-09-21 2014-06-03 Merck Sharp & Dohme B.V. Drug delivery system
US20090105346A1 (en) * 2007-10-02 2009-04-23 Alexandr Jegorov Novel crystalline forms of armodafinil and preparation thereof
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US10596103B2 (en) 2013-12-11 2020-03-24 Merek Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement
EP4210709B1 (en) * 2020-09-14 2025-10-29 Pharma Cinq, LLC 2',3'-diacetyluridine substituted with acetoacetyl at the 5' position

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177290A (en) * 1977-03-31 1979-12-04 Laboratoire L. Lafon Acetamide derivatives

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1520812A (en) * 1975-10-02 1978-08-09 Lafon Labor Benzhydrylsulphinyl derivatives
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2684875B1 (fr) 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
FR2697162B1 (fr) 1992-10-23 1995-01-13 Lafon Labor Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
FR2706767B1 (https=) * 1993-06-22 1995-09-08 Lafon Labor
FR2707637B1 (fr) 1993-06-30 1995-10-06 Lafon Labor Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique.
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
FR2771004B1 (fr) * 1997-11-19 2000-02-18 Inst Curie Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IL128989A0 (en) 1999-03-15 2000-02-17 Popov Sergey Safety trocar assembly
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) * 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2804322B1 (fr) * 2000-01-31 2002-04-19 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies
US6492396B2 (en) * 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
CZ2003529A3 (cs) * 2000-07-27 2003-09-17 Teva Pharmaceutical Industries Ltd. Krystalický a čistý modafinil a postup jeho přípravy
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
CZ2004446A3 (cs) 2001-09-07 2005-01-12 Teva Pharmaceutical Industries Ltd. Krystalické formy valaciklovir hydrochloridu
US6875893B2 (en) * 2002-05-23 2005-04-05 Cephalon, Inc. Preparations of a sulfinyl acetamide
US6992219B2 (en) 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
US20040242698A1 (en) 2003-05-13 2004-12-02 Cephalon Inc. Analeptic and antidepressant combinations
US20040229941A1 (en) 2003-05-13 2004-11-18 Cephalon, Inc. Analeptic and antidepressant combinations
AR045423A1 (es) 2003-05-13 2005-10-26 Cephalon Inc Combinaciones de analiticos y antidepresivos
AR045314A1 (es) 2003-05-13 2005-10-26 Cephalon Inc Composiciones farmaceuticas de analepticos y antidepresivos
US20040229943A1 (en) 2003-05-16 2004-11-18 Cephalon Inc Analeptic and drug combinations
ES2330321T3 (es) 2003-05-16 2009-12-09 Cephalon France Procedimiento de sintesis de modafinilo.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177290A (en) * 1977-03-31 1979-12-04 Laboratoire L. Lafon Acetamide derivatives

Also Published As

Publication number Publication date
ZA200500411B (en) 2006-07-26
US20040102523A1 (en) 2004-05-27
AU2003253128A1 (en) 2004-02-25
JP5307106B2 (ja) 2013-10-02
US7405323B2 (en) 2008-07-29
CA2746788A1 (en) 2004-02-19
JP2011046730A (ja) 2011-03-10
CN102875429A (zh) 2013-01-16
US20080153918A1 (en) 2008-06-26
US7649020B2 (en) 2010-01-19
CA2804385A1 (en) 2004-02-19
IL166301A (en) 2011-06-30
EP2402311A1 (en) 2012-01-04
CA2746788C (en) 2013-04-09
IL209965A0 (en) 2011-07-31
IL166301A0 (en) 2006-01-15
CA2494010C (en) 2011-10-18
CA2494010A1 (en) 2004-02-19
NZ537840A (en) 2007-01-26
CA2840721C (en) 2015-06-16
CA2840721A1 (en) 2004-02-19
CN102875430A (zh) 2013-01-16
IL209966A (en) 2013-02-28
CN1675177A (zh) 2005-09-28
EP1575915A1 (en) 2005-09-21
MXPA05001506A (es) 2005-08-16
WO2004014846A1 (en) 2004-02-19
CN102875429B (zh) 2014-12-10
JP2005535698A (ja) 2005-11-24
US6992219B2 (en) 2006-01-31
US20060252835A1 (en) 2006-11-09
AU2003253128B2 (en) 2009-01-29
IL209966A0 (en) 2011-07-31
JP4718177B2 (ja) 2011-07-06

Similar Documents

Publication Publication Date Title
CN100506790C (zh) 莫达非尼多晶型
JP2005535698A5 (https=)
US20210292280A1 (en) Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
WO2014059702A1 (zh) 苯磷硫胺多晶型体、制备方法及其应用
CN104098570A (zh) 替卡格雷晶型及其制备方法和用途
WO2010060387A1 (zh) 硝克柳胺化合物五种晶型、其制法和其药物组合物与用途
CN101619033B (zh) 莫达非尼多晶型
CN105085421B (zh) 奥比特嗪‑富马酸盐、水合物、晶型及其制备方法
CN112851640B (zh) 嘧啶苯甲酰胺化合物的硫酸盐及其用途
CN104098575B (zh) 一种盐酸依匹斯汀晶型及其制备方法和用途
CN118984818A (zh) 环己酮化合物的晶型
JP2025092721A (ja) 化合物の結晶形、その製造方法及び使用
JP2026500850A (ja) ペオニフロリン一水和物の結晶型ａおよびその調製方法と使用
JP2025513893A (ja) ７，８－ジヒドロキシフラボンの結晶多形およびその調製方法
AU2024320769A1 (en) Crystal form vi of acrylamide compound, and preparation method therefor and use thereof
JP2022087834A (ja) 放出調節製剤およびその使用
TW201107324A (en) Process for optimizing the particle size of an active pharmaceutical ingredient by crystallization

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: CEPHALON FRANCE

Free format text: FORMER OWNER: CEPHALON FRANCE; APPLICANT

Effective date: 20070518

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20070518

Address after: French Maisons Alfort

Applicant after: Cephalon France

Address before: French Maisons Alfort

Applicant before: Cephalon France

Co-applicant before: Osmond World Synthetic Organization

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: CEPHALON EUROPE CORP.

Free format text: FORMER OWNER: CEPHALON FRANCE

Effective date: 20150804

Owner name: TEVA SANTE S. A. S.

Free format text: FORMER OWNER: CEPHALON EUROPE CORP.

Effective date: 20150804

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20150804

Address after: Paris France

Patentee after: Teva Sant Co.

Address before: French Maisons Alfort

Patentee before: Saifulun European Co.

Effective date of registration: 20150804

Address after: French Maisons Alfort

Patentee after: Saifulun European Co.

Address before: French Maisons Alfort

Patentee before: Cephalon France

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090701

Termination date: 20150808

EXPY Termination of patent right or utility model